When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease 'in their genes'? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself.
Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform. Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the mechanism that determines which genes are expressed and to what degree, influenced by factors such as diet, exercise, stress, and environmental exposures.
The implications of this approach are profound. Traditional risk assessment tools, such as cholesterol levels and blood pressure, can miss significant risks, especially in younger individuals or those without obvious symptoms. By analyzing epigenetic markers, Cardio Diagnostics aims to uncover hidden heart disease risks that might otherwise go undetected until a cardiac event occurs. This could lead to earlier interventions and personalized prevention strategies, potentially reducing the burden of cardiovascular disease, which remains the leading cause of death globally.
Epigenetics does more than pinpoint a problem; it also provides some level of solution, according to the company's CEO. Because epigenetic changes are reversible, understanding a patient's epigenetic profile can guide lifestyle modifications or treatments that may modify those markers and reduce risk. For example, a person with a specific epigenetic pattern associated with inflammation might benefit from anti-inflammatory diets or medications, while another with patterns linked to oxidative stress could focus on antioxidant-rich foods.
Cardio Diagnostics' platform represents a shift from one-size-fits-all medicine to a more nuanced understanding of individual risk. The company's tests are designed to be accessible and actionable, aiming to empower both patients and physicians with data that goes beyond traditional metrics. As the field of epigenetics continues to evolve, such diagnostics could become standard in cardiovascular care, offering a window into the dynamic interplay between genes and environment.
For investors, Cardio Diagnostics is at the forefront of a rapidly growing area of precision medicine. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
